CenterBook Partners LP Has $1.85 Million Stake in Natera, Inc. $NTRA

CenterBook Partners LP lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 76.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,053 shares of the medical research company’s stock after selling 25,642 shares during the period. CenterBook Partners LP’s holdings in Natera were worth $1,845,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Palladiem LLC bought a new position in shares of Natera during the 4th quarter worth approximately $31,000. Horizon Investments LLC bought a new position in shares of Natera during the 3rd quarter worth approximately $32,000. Flagship Harbor Advisors LLC bought a new position in shares of Natera during the 4th quarter worth approximately $41,000. Sound Income Strategies LLC lifted its position in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after buying an additional 45 shares in the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Natera during the 4th quarter worth approximately $62,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Fesko sold 1,438 shares of Natera stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the completion of the sale, the insider directly owned 185,782 shares in the company, valued at $37,684,020.88. This trade represents a 0.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 159,500 shares of company stock worth $34,664,208 in the last three months. Insiders own 5.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on NTRA. The Goldman Sachs Group began coverage on shares of Natera in a research report on Friday. They set a “neutral” rating and a $245.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. Wells Fargo & Company lifted their target price on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Morgan Stanley dropped their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $256.12.

Natera Trading Up 4.4%

NASDAQ:NTRA opened at $222.82 on Wednesday. The stock has a market capitalization of $31.91 billion, a PE ratio of -136.70 and a beta of 1.56. The firm’s 50 day moving average is $205.34 and its 200 day moving average is $216.16. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.